Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies
- PMID: 29325867
- PMCID: PMC5817633
- DOI: 10.1016/j.pnpbp.2018.01.004
Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies
Abstract
Atypical antipsychotics increase the risk of diabetes and cardiovascular disease through their side effects of insulin resistance and weight gain. The populations for which atypical antipsychotics are used carry a baseline risk of metabolic dysregulation prior to medication which has made it difficult to fully understand whether atypical antipsychotics cause insulin resistance and weight gain directly. The purpose of this work was to conduct a systematic review and meta-analysis of atypical antipsychotic trials in healthy volunteers to better understand their effects on insulin sensitivity and weight gain. Furthermore, we aimed to evaluate the occurrence of insulin resistance with or without weight gain and with treatment length by using subgroup and meta-regression techniques. Overall, the meta-analysis provides evidence that atypical antipsychotics decrease insulin sensitivity (standardized mean difference=-0.437, p<0.001) and increase weight (standardized mean difference=0.591, p<0.001) in healthy volunteers. It was found that decreases in insulin sensitivity were potentially dependent on treatment length but not weight gain. Decreases in insulin sensitivity occurred in multi-dose studies <13days while weight gain occurred in studies 14days and longer (max 28days). These findings provide preliminary evidence that atypical antipsychotics cause insulin resistance and weight gain directly, independent of psychiatric disease and may be associated with length of treatment. Further, well-designed studies to assess the co-occurrence of insulin resistance and weight gain and to understand the mechanisms and sequence by which they occur are required.
Keywords: Antipsychotic; Insulin; Meta-analysis; Weight.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
None of the authors have conflicts of interest to disclose relating to the content of the article.
Figures





References
-
- Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S, Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis. World psychiatry : official journal of the World Psychiatric Association (WPA) 2016;15(2):166–74. doi: 10.1002/wps.20309. Epub 2016/06/07. - DOI - PMC - PubMed
-
- Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World psychiatry : official journal of the World Psychiatric Association (WPA) 2015;14(3):339–47. doi: 10.1002/wps.20252. Epub 2015/09/27. - DOI - PMC - PubMed
-
- Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K. First-v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. The British journal of psychiatry : the journal of mental science. 2008;192(6):406–11. doi: 10.1192/bjp.bp.107.037184. Epub 2008/06/03. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical